small molecule

SAXAGLIPTIN

SAXAGLIPTIN HYDROCHLORIDE

Loss of exclusivity—loss of exclusivity
CompanyAmneal Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameSAXAGLIPTIN
Active ingredientSAXAGLIPTIN HYDROCHLORIDE
StrengthEQ 2.5MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalJuly 2023
Marketing statusDISCN

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.